ClinicalTrials.gg
CompletedNCT04540016Updated Dec 12, 2022

Mass Balance and Biotransformation of [14C]HSK7653 in Human

A Phase 1 interventional study of [14C]HSK7653 in Type II Diabetes, sponsored by Sichuan Haisco Pharmaceutical Group Co., Ltd. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-12-12.

Sponsored by Sichuan Haisco Pharmaceutical Group Co., Ltd (part of Haisco Pharmaceutical Group Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 909 studies in Diabetes Mellitus, Type 2 with a site in China — 205 open to participants now, 228 under way, 46 of them phase 3. Diabetes Mellitus, Type 2 · China.

Enrollment
762nd of 767
6 · median 199
Started
2020
with 49 others
Phase 1
122 of 909
12 open now
Registered
434th of 909
by date

Among the 909 studies in Diabetes Mellitus, Type 2 with a site in China, this one is the 762nd largest by enrollment of the 767 interventional ones that give a count, is one of 50 that started in 2020, is one of 122 in phase 1, and was the 434th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

205 of the 909 studies in Diabetes Mellitus, Type 2 with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 909 studies in Diabetes Mellitus, Type 2 with a site in China, or all of them as a file.
02

Study summary

A single-center, single-dose, non-randomized, open-label design.

Read the detailed description

Six healthy adult male subjects will be enrolled and the trial will be carried out in two steps:

Step 1: Two eligible male subjects are enrolled and admitted to the clinical study site after passing verification against inclusion and exclusion criteria on Day -2. After being admitted, the subjects are trained regarding drug administration and urine and stool collection procedures to ensure that they are able to perform relevant operations according to the protocol and SOP requirements. Subjects are deprived of food for at least 10 h and of water for 1 h before drug administration. After oral administration of investigational product in the morning of Day 1 under fasted condition, each subject will be deprived of food for 4 h and of water for 1 h.

Dense sampling is scheduled for all urine and stool samples excreted at specified time intervals within 0-336 h post-dose as well as blood samples at specified time points within 0-336 h post-dose. Sample collection and corresponding safety monitoring will be completed in the morning of Day 15 (the specific time will be decided by the investigator and sponsor based on the phased test results, safety results, and the actual situation) before the subjects leave the phase I clinical trial ward. Subjects will return to the ward on Days 19, 26, 33, and 40 to complete biological sample collection and vital sign monitoring according to protocol requirements. Subjects will return to the ward on Day 47 to complete the last biological sample collection (scheduled to be 1176 h after administration) and various withdrawal examinations according to protocol requirements.

The trial employs phased testing to determine whether the dense sampling and sparse sampling time points should be adjusted and whether collection of blood, urine, and stool samples can be prematurely stopped or should be continued for an extended period based on the test results. If biological sampling duration exceeds 1176 h in this study, then sampling will continue at an interval of 7 days until the protocol-specified evaluation criteria for sampling termination is satisfied. Safety monitoring will continue until the date of sampling completion. The test results in step 1 will be used to determine whether the trial procedure needs to be adjusted.

Step 2: Four eligible male subjects will be enrolled and blood, urine, and stool samples will be collected at specified time points/intervals. The procedures are the same as step 1.

Criteria for sampling termination:

Excretion: The radioactivity of biological samples (urine + stool) collected over two consecutive time intervals from the subject is less than 1% of the dose.

Radioactive blood samples: Plasma radioactivity concentrations at two consecutive time points are \< 3 times background plasma concentration.

The target total radioactivity of biological samples (urine + stool) collected from each subject is not lower than 80% of the dose. The investigator should finally determine whether to stop sampling of a subject based on the comprehensive evaluation of radioactive test results, safety results and the actual situation.

The entire trial is based on the complete test samples and data collected from 6 subjects. All subjects must complete the trial procedures according to the protocol requirements during admission in the clinical study site and they are not allowed to leave the clinical study site without permission by the investigator.

Subject may withdraw from the study upon confirmation by the investigator provided that no clinically significant abnormality is observed in clinical observation after completion of the trial. Should any clinically significant abnormality be found, the subject will continue to stay at the study site for observation or leave the study site after comprehensive assessment by the investigator and periodically (usually 7 days from the last test) return to the hospital for retests and followed up until recovery to normal, the abnormality is not clinically significant, or a level deemed acceptable by the investigator.

03

Conditions studied

  • Type II Diabetes
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy Chinese males, aged 18-45 years old (inclusive);
  2. Body weight ≥ 50.0 kg and (BMI) between 19.0-26.0 kg/m2 (inclusive);
  3. Subjects who voluntarily sign the form (ICF), able to communicate with the investigator and to complete all trial procedures as per the protocol.-

Exclusion criteria

Exclusion Criteria:

Those who meet any of the following should not be enrolled:

Clinical examination:

  1. abnormal results for comprehensive physical examination, vital signs, routine laboratory tests [blood routine, blood biochemistry, coagulation routine, urine routine, stool routine + occult blood, thyroid function, oral glucose tolerance test (fasting blood glucose, 2-hour blood glucose), ], visual acuity and ophthalmic examination (slit lamp, introcular pressure, and fundoscopy), 12-lead (ECG), chest X-ray (anteriorposterior), and abdominal B-ultrasound (liver, gallbladder, pancreas, spleen, and kidney);
  2. Positive for surface antigen or E antigen, antibody, antibody, or Treponema pallidum antibodies;

    Medication history:

  3. Use of any Western medicine or Chinese patent medicine (including prescription drug, over-the-counter drug, health care product, or live attenuated influenza vaccine) within 14 days prior to screening;
  4. Participation in any clinical trial and interference with other drug or medical device within 3 month prior to screening;

    Medical history and surgical history:

  5. History of serious clinical diseases or diseases/conditions that the investigator believes may affect the study results, including but not limited to the history of diseases in the motor system, nervous system, endocrine system, circulatory system, respiratory system, digestive system, urinary system, and reproductive system;
  6. Past history of organic heart disease, heart failure, myocardial infarction, angina, unexplained arrhythmia, torsades de pointes, ventricular tachycardia, long syndrome or symptoms and familial history of long QT syndrome (indicated by genetic evidence or sudden death of a close relative at a young age due to cardiac causes);
  7. Have undergone major surgery within 6 months prior to screening or with incomplete healing of the surgical incision; major surgery includes, but is not limited to, any surgery with significant risk of bleeding, prolonged general anesthesia, or incisional or obvious traumatic injury (excluding cured appendicitis surgery or rectal prolapse surgery);
  8. Severe allergic constitution, including known allergy to DPP-4 inhibitors or any of this investigational product (mannitol, microcrystalline cellulose), two or more drugs and food components, or with special dietary requirements and thus unable to follow a standardized diet;
  9. With commitment acute/chronic bronchospasm (asthma, ), pulmonary fibrosis, pulmonary tuberculosis, untreated pneumonitis, or other diseases that affect respiratory function;
  10. History of severe hypoglycemic seizure (such as hypoglycemia-induced somnolence, disturbance of consciousness, disorganized speech, or even coma), or history of severe hypoglycemia unawareness;
  11. Volunteers judged by the investigator to be unsuitable for participating in this trial for any reason.-
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Other
    Arm Ⅰ

    25 mg of 80 µCi \[14C\]HSK7653.

    Drug: [14C]HSK7653

Interventions

  • 25 mg of \[14C\]HSK7653 (radioactivity of 80 µCi) capsules are taken under fasted condition.

06

What researchers measure

Primary outcomes

  1. Percentage of cumulative drug excretion of [14C]HSK7653 on biological specimens(urine and faeces) accounting for total radiation drug dose

    Though collecting different periods of biological specimens(urine and faeces) , detecting their respective drug excretion of \[14C\]HSK7653,calculating the total cumulative excretion amount and relevant proportion of each kind of specimen(urine or faeces).

    Time frame: From the start of administration to 50 day after administration

  2. Peak concentration (Cmax)

    Pharmacokinetic Measures

    Time frame: From the start of administration to 50 day after administration

  3. Area under the concentration-time curve (AUC0-t, AUC0-∞)

    Pharmacokinetic Measures

    Time frame: From the start of administration to 50 day after administration

07

Study locations

1 site
  • the First Affilicated Hospital of Soochow University
    Suzhou, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Jan 2021, 1 month.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 1 month is below that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2020
First posted
Sep 7, 2020
StartActual
Nov 15, 2020
Primary completionActual
Jan 14, 2021
CompletionActual
Jan 21, 2021
Last update
Dec 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04540016
Collaborators
First Affiliated Hospital of Suzhou Medical College
Responsible party
Sponsor
First posted
Sep 7, 2020
Start date
Nov 15, 2020
Primary completion
Jan 14, 2021
Completion
Jan 21, 2021
Last update
Dec 12, 2022

Study contacts

Liyan Miao, PhD
principal investigator · Medical Ethics Committee of the First Affiliated Hospital of soochow University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HSK7653

Start the discussion